Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. Biogen markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis, FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy.
Company Growth (employees)
Cambridge, US
Size (employees)
7,400 (est)
Biogen was founded in 1978 and is headquartered in Cambridge, US

Key People/Management at Biogen

Michel Vounatsos

Michel Vounatsos


Biogen Office Locations

Biogen has an office in Cambridge
Cambridge, US (HQ)
225 Binney St

Biogen Financials and Metrics

Biogen Financials

Biogen's revenue was reported to be $2.8 b in Q1, 2017

Revenue (Q1, 2017)

2.8 b

Net income (Q1, 2017)

747.5 m

EBIT (Q1, 2017)

1 b

Market capitalization (20-Oct-2017)

71.7 b

Cash (31-Mar-2017)

924 m
Biogen's current market capitalization is $71.7 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


6.9 b9.7 b10.8 b11.4 b

Revenue growth, %


R&D expense

2 b

General and administrative expense

1.9 b
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


2.4 b2.5 b2.6 b2.6 b2.8 b2.7 b2.9 b3 b2.8 b

R&D expense

447.3 m417.2 m460.5 m490.7 m519.9 m437.3 m473.1 m529 m423.4 m

General and administrative expense

576.6 m570.4 m560.4 m491.9 m477.8 m497.3 m492.4 m462.7 m499.1 m

Operating expense total

1 b987.6 m1 b982.6 m997.7 m934.6 m965.5 m991.7 m922.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


602.6 m1.2 b1.3 b2.3 b

Accounts Receivable

824.4 m1.3 b1.2 b1.4 b


659 m804 m893.4 m1 b

Current Assets

3.2 b4.7 b6.7 b8.7 b
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


863.2 m1.2 b1.5 b1.3 b4.1 b1.1 b1.4 b2.1 b924 m

Accounts Receivable

1 b1.1 b1.4 b1.3 b1.3 b1.4 b1.3 b1.5 b1.5 b


715.9 m753.1 m825.3 m865.7 m918.9 m964.6 m996.4 m1 b921.6 m

Current Assets

3.9 b4.4 b5.3 b5.6 b9.3 b7.2 b7.4 b8.1 b6.9 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

1.9 b2.9 b3.6 b3.7 b

Depreciation and Amortization

688.2 m600.4 m682.7 m

Accounts Receivable

(130 m)(510 m)29 m(241.4 m)


(240 m)(190 m)(170 m)(165.6 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

723.1 m856.1 m820.2 m924.8 m1 b969.2 m1 b1 b747.5 m

Accounts Receivable

1.3 b1.3 b1.4 b1.3 b1.5 b1.5 b


865.7 m918.9 m964.6 m996.4 m1 b921.6 m

Accounts Payable

282.7 m251.2 m271.3 m225.9 m274 m316.4 m
USDY, 2017


379.8 k

Financial Leverage

1.8 x
Show all financial metrics

Biogen Operating Metrics

Biogen's Training Provided, no. of people was reported to be 40 k in FY, 2016
FY, 2016

Training Provided, no. of people

40 k

Phase III Trials


Phase II Trials


Phase I Trials

Show all operating metrics

Biogen Market Value History

Biogen Median Salaries

Source: 109 public H-1B filings from Biogen

Traffic Overview of Biogen

Biogen Online and Social Media Presence

Biogen News and Updates

Rep. Cummings to Trump: It's time to force lower prices on Biogen's new MS drug Zinbryta

Rep. Elijah Cummings, D-Md., is urging President Donald Trump to twist some arms at Biogen. The biotech's new multiple sclerosis drug Zinbryta, developed with the help of taxpayer-funded research, costs too much, he argued, and Trump should use his power to push a price cut.

Recombinant Coagulation Factors Market by Regional Analysis, Key Players and Forecast 2025

Recombinant coagulation factors, as opposed to plasma-derived counterparts, consume a very low risk for transfer of infectious diseases and their use would eliminate the risk of infection from viruses such as the human immunodeficiency virus and hepatitis C. Posted via Industry Today. Follow us on …

Merck KGaA to take on Biogen, Novartis with long-sought EMA nod for MS pill

Six years after regulators in both the U.S. and Europe said they wouldn’t approve Merck KGaA’s oral multiple sclerosis drug, cladribine, the German company has scored an unlikely victory, winning European approval to market it in 28 countries. But competing with more established rivals won't be easy…

Biogen, Samsung Humira copy wins EU approval

The forces of competition are mounting against Humira, the world’s best-selling drug at $16 billion in global sales, with approval of a second biosimilar in Europe.

Bioverativ taps patient social network for input on hemophilia trial design

What if companies knew patients’ top unmet needs before they began clinical trials and could factor them into studies—potentially paving the way for marketers to talk up a variety of benefits down the line? Bioverativ is about to find out.

Goldman Sachs Bet on Biogen’s Potential Landmark Alzheimer’s Drug Props Up Stock

Goldman analysts think the drug could eventually ring in $12 billion in sales if approved.
Show more

Biogen Company Life and Culture

You may also be interested in